NCT04844385View on ClinicalTrials.gov

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

February 20, 2021

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2024

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Toripalimab

Toripalimab 240 mg, d1, Q3w for two cycles

DRUG

Paclitaxel-albumin

Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles

DRUG

Nedaplatin

Nedaplatin 75mg/m2, d1, Q3w for two cycles

RADIATION

radiation therapy at a total dose 60 Gy

Radiation therapy at a total dose 60 Gy

DRUG

Capecitabine

Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy

RADIATION

radiation therapy at a total dose 50 Gy

Radiation therapy at a total dose 50 Gy

Trial Locations (1)

510000

Sun yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER